Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918105 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL25323350 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29345090 | 0.86 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL25323352 | 0.86 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29202406 | 0.84 | NR1H2 (0.39) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL9918104 | 0.84 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29081315 | 0.82 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29081317 | 0.82 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL1630474 | 0.81 | HTT (0.43) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL1630475 | 0.81 | HTT (0.43) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009124956-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NR1H2 344/4885CHRM2 778/4885CHRM1 666/4885 |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | HCRTR2, HCRTR1, NPY4R | NR1H2 345/4885CHRM2 322/4885CHRM1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.